(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash. Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday. Under the terms of agreement, Avidity will separate its early-stage precision cardiology programs into a new company called Spinco. Novartis has been actively striking deals in 2025 as it looks to bolster its drug pipeline and drive future growth, and the Financial Times reported in August that the Swiss drugmaker had approached Avidity Biosciences for a potential takeover offer. (Reporting by Angela Christy in Bengaluru)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
New Delhi [India], March 21: India’s entrepreneurial landscape is changing rapidly. More women today are…
PKF managing trustee, Sundeep Bhutoria (inset). PKF and World WWF-India will jointly present the 6th…
Dr. A.K. Dwivedi’s Campaign Reaches Over 2 Million People Indore (Madhya Pradesh) [India], March 19:…
Surat (Gujarat) [India], March 20: Surat emerged as the meeting point of India’s entrepreneurial leadership…
Platform brings youth, industry and incubators together to explore entrepreneurship as an emerging livelihood pathway…
Mumbai (Maharashtra) [India], March 19: Central Depository Services (India) Limited (“CDSL”), Asia’s first listed depository,…